New York Approves Biodesix's Veristrat Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Biodesix said on Tuesday that it has received certification from the New York State Department of Health to offer its VeriStrat serum proteomic test.

As a result, the test, which is to help guide doctors in the treatment of patients with non-small cell lung cancer, is available in all 50 states. The test is performed in Biodesix's CLIA laboratory.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.